Signaling pathways
-
BA6041 StapokibartSummary: Stapokibart (CM310) is a targeted humanized monoclonal antibody that effectively blocks the interaction of cytokines and their co-receptor subunit IL-4Rα. -
BA6042 KeliximabSummary: Keliximab (SB-210396) is a chimeric human/rhesus monkey anti-monoclonal antibody. -
BA6043 IL-2-IN-1Summary: IL-2-IN-1 is a potent inhibitor. -
BA6044 ErepdekinraSummary: An interleukin-17A receptor antagonist. -
BA6045 NO-prednisoloneSummary: NO-prednisolone is a derivative of prednisolone that releases nitric oxide (NO). -
BA6046 BMS-986251Summary: BMS-986251 is an orally active, selective inverse agonist. -
BA6047 RademikibartSummary: Rademikibart (CBP-201) is a targeted human monoclonal antibody with a KD of 20.7 pM when bound to the human IL-4Rα epitope. -
BA6048 CasdozokitugSummary: Targeted IgG1κ antibodies. -
BA6049 Lys-D-Pro-ThrSummary: Lys-D-Pro-Thr, an IL-1beta analog, is a potent inhibitor. -
BA6050 NLRP3-IN-25Summary: NLRP3-IN-25 is an orally effective inhibitor with anti-inflammatory activity.

